Research Study Summary
Research Study for Chronic Obstructive Pulmonary Disease (COPD)
This is a research study for chronic obstructive pulmonary disease (COPD). Subjects who meet
inclusion criteria will be assigned to one of three doses of tiotropium. Two of these doses will be delivered via a novel inhalation device. The third dose will be delivered by the HandiHaler.
This study is for male and female patients age 40 or older who meet spirometry criteria. Patients may not have any other significant respiratory diseases. Oxygen will be allowed if used less than 12 hours per day.
This study is expected to last 2 to 3 ½ years and consist of approximately 10-17 treatment visits. This may change depending on the number of events reported to the pharmaceutical company. At the screening visit, subjects will have a physical examination, EKG and may perform pulmonary function testing at no charge. Subsequent visits will consist of assessment of health and possibly pulmonary function testing. Visit intervals will be from 6 to 12 weeks with interim telephone contacts to assess health and well being.
All study related medication and assessments will be at no charge to the participant. Subjects will be reimbursed for their time and travel.
To Learn more
CW ID: 165992
Date Last Changed:
July 23, 2013
Clinical Trial Snapshot
- Both Male and Female
- 40 and up
- Overall Status
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.